HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 65.20% from the company’s current price. HC Wainwright also issued estimates for Theravance Biopharma’s FY2028 earnings at $1.11 EPS and FY2029 earnings at $3.87 EPS.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $9.08 on Tuesday. The business has a 50 day simple moving average of $9.35 and a 200 day simple moving average of $8.91. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $10.90. The stock has a market cap of $446.50 million, a price-to-earnings ratio of -8.99 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. On average, analysts predict that Theravance Biopharma will post -1.09 EPS for the current year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Aquatic Capital Management LLC bought a new position in Theravance Biopharma in the 4th quarter worth $25,000. Quantbot Technologies LP acquired a new stake in shares of Theravance Biopharma in the third quarter valued at about $60,000. KLP Kapitalforvaltning AS bought a new position in shares of Theravance Biopharma in the fourth quarter worth about $69,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,696 shares during the period. Finally, Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma during the 4th quarter worth about $103,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.